Compare Ross Stores, Inc. (ROST) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs 10X Genomics Inc — how do they compare? Ross Stores, Inc. trades at $226 (market cap $71.94B), while 10X Genomics Inc trades at $79 (market cap $10.07B). The key difference: Ross Stores, Inc. is far larger — about 7.1× 10X Genomics Inc's market cap, and Ross Stores, Inc. pays a 0.79% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and 10X Genomics Inc for 92 Days on average.
| ROST | TXG | |
|---|---|---|
Market Cap | $71.94B | $10.07B |
Volume | 2,002,519 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $97.74 |
52-Week Low | $147.71 | $11.48 |
Typical Hold Time | 48 Days | 92 Days |
Enterprise Value | $72.39B | $9.59B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $225.53, up 0.59% today, with a bearish technical signal but strong fundamental performance. The stock shows robust profitability with a net income margin of 10.85% and ROE of 42.63%, supported by consistent earnings beats in recent quarters. Revenue growth trends upward, reaching $21.13B in 2025, while analyst consensus remains bullish with a $274.14 price target. Recent news highlights store expansion and value-focused strategies attracting shoppers amid competitive retail pressures.
The outlook for ROST is positive based on earnings momentum and strategic initiatives, though technical indicators suggest near-term caution. Risks include rising costs and market volatility, but institutional buying and high ROE provide support. The stock offers growth potential if execution on expansion continues, with downside cushioned by strong cash flow and analyst optimism.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
